Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Synthetic Biologics Inc (NYSE MKT LLC:SYN)

3.23
Delayed Data
As of Aug 03
 +0.05 / +1.57%
Today’s Change
1.34
Today|||52-Week Range
4.32
+121.23%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$281.5M

Company Description

Synthetic Biologics, Inc. is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The company developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of C. diff infection, an oral treatment to reduce the impact of methane producing organisms on conditions such as constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. Synthetic Biologics was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Contact Information

Synthetic Biologics, Inc.
155 Gibbs Street
Rockville Maryland 20850
P:(734) 332-7800
Investor Relations:

Employees

Shareholders

Mutual fund holders3.41%
Individual stakeholders23.25%
Other institutional12.26%

Top Executives

Jeffrey Lucero RileyPresident, Chief Executive Officer & Director
Steven A. ShallcrossChief Financial Officer, Secretary & Treasurer
John James MonahanExecutive Vice President-Research & Development
Joseph SlimanSenior VP-Clinical & Regulatory Affairs
Lara M. GuzmanSenior Director-Project Operations